Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
117
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study

Jindi Zhang1 Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Pudong, Shanghai200126, People’s Republic of China;2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6559-977X
ORCID Icon,
Anyang Li2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of China
,
Qi Jiang2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of China
,
Feiyun Zheng2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of China
&
Haiyan Zhu1 Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Pudong, Shanghai200126, People’s Republic of China;2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of ChinaCorrespondence[email protected]
Pages 3913-3918 | Published online: 15 Nov 2019

References

  • Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.2126225651787
  • Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–953. doi:10.1056/NEJMoa090880620818904
  • Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019. doi:10.3322/caac.21559
  • Ding J, Chen X, Gao Z, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013;41:1195–1210. doi:10.1124/dmd.112.05031023509226
  • Miao M, Deng G, Luo S, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2018;148:286–290. doi:10.1016/j.ygyno.2017.12.01329248198
  • Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19:1239–1246. doi:10.1016/S1470-2045(18)30349-830082170
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-124713220175033
  • Guppy AE, Rustin GJ. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002;7:437–443. doi:10.1634/theoncologist.7-5-43712401906
  • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181. doi:10.1016/S1053-4296(03)00031-612903007
  • Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol. 2016;27(Suppl 1):i33–i9. doi:10.1093/annonc/mdw09327141068
  • Zhang W, Shen Z, Luo H, et al. The benefits and side effects of bevacizumab for the treatment of recurrent ovarian cancer. Curr Drug Targets. 2017;18:1125–1131. doi:10.2174/138945011766616050215023727138763
  • Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–1308. doi:10.1200/JCO.2013.51.448924637997
  • Bodnar L, Gornas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol. 2011;123:33–36. doi:10.1016/j.ygyno.2011.06.01921723597
  • Orbegoso C, Marquina G, George A, et al. The role of Cediranib in ovarian cancer. Expert Opin Pharmacother. 2017;18:1637–1648. doi:10.1080/14656566.2017.138338428933580
  • Ding J, Cheng XY, Liu S, et al. Apatinib exerts anti-tumour effects on ovarian cancer cells. Gynecol Oncol. 2019;153:165–174. doi:10.1016/j.ygyno.2019.01.01030651189
  • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–2045. doi:10.1200/JCO.2012.42.050522529265
  • Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–2496. doi:10.1056/NEJMoa110379922204725
  • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–2483. doi:10.1056/NEJMoa110439022204724
  • Jin M, Cai J, Wang X, et al. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review. Cancer Biol Ther. 2018;19:1–5.29281559
  • Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165–5171. doi:10.1200/JCO.2007.11.534518024863
  • Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180–5186. doi:10.1200/JCO.2007.12.078218024865
  • Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11:172–191. doi:10.1016/j.ejcsup.2013.07.01626217127
  • Hu X, Cao J, Hu W, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. doi:10.1186/1471-2407-14-82025376790

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.